Literature DB >> 12675924

CAT2 arginine transporter deficiency significantly reduces iNOS-mediated NO production in astrocytes.

Cathyryne K Manner1, Benjamin Nicholson, Carol L MacLeod.   

Abstract

We have previously demonstrated that genetic ablation of cationic amino acid transporter 2 (Cat2) significantly inhibits nitric oxide (NO) production by inducible nitric oxide synthase (iNOS) in activated macrophages. Here we report that iNOS activity is impaired by 84% in activated Cat2-deficient astrocytes. Cat2 ablation appears to reduce astrocyte NO synthesis by decreasing the uptake of the sole precursor, arginine, as well as by reducing the expression of iNOS following activation. Excessive or dysregulated NO production by activated astrocytes and other CNS cell types has been implicated in the pathogenesis of neurological disorders. Our results support the idea that manipulation of CAT2 transporter function might be useful for the therapeutic modulation of iNOS activity.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12675924     DOI: 10.1046/j.1471-4159.2003.01695.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  14 in total

Review 1.  Structure and function of cationic amino acid transporters (CATs).

Authors:  E I Closs; J-P Boissel; A Habermeier; A Rotmann
Journal:  J Membr Biol       Date:  2007-04-06       Impact factor: 1.843

2.  Characterization of cationic amino acid transporters (hCATs) 1 and 2 in human skin.

Authors:  Kristin Jaeger; Friedrich Paulsen; Johannes Wohlrab
Journal:  Histochem Cell Biol       Date:  2008-01-03       Impact factor: 4.304

3.  UGGT1 retains proinsulin in the endoplasmic reticulum in an arginine dependent manner.

Authors:  Jaeyong Cho; Masaki Hiramoto; Yuka Masaike; Satoshi Sakamoto; Yoichi Imai; Yumi Imai; Hiroshi Handa; Takeshi Imai
Journal:  Biochem Biophys Res Commun       Date:  2020-05-16       Impact factor: 3.575

4.  Phenotype and Function of Myeloid-Derived Suppressor Cells Induced by Porphyromonas gingivalis Infection.

Authors:  Lingkai Su; Qingan Xu; Ping Zhang; Suzanne M Michalek; Jannet Katz
Journal:  Infect Immun       Date:  2017-07-19       Impact factor: 3.441

5.  Nitric oxide suppression of cellular proliferation depends on cationic amino acid transporter activity in cytokine-stimulated pulmonary endothelial cells.

Authors:  Louis G Chicoine; Louis G Chicione; Michael R Stenger; Hongmei Cui; Andrea Calvert; Rebecca J Evans; B Keith English; Yusen Liu; Leif D Nelin
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2011-01-14       Impact factor: 5.464

6.  T Cells Encountering Myeloid Cells Programmed for Amino Acid-dependent Immunosuppression Use Rictor/mTORC2 Protein for Proliferative Checkpoint Decisions.

Authors:  Lee-Ann Van de Velde; Chitra Subramanian; Amber M Smith; Luke Barron; Joseph E Qualls; Geoffrey Neale; Adolfo Alfonso-Pecchio; Suzanne Jackowski; Charles O Rock; Thomas A Wynn; Peter J Murray
Journal:  J Biol Chem       Date:  2016-11-30       Impact factor: 5.157

Review 7.  Inducible nitric oxide synthase: Regulation, structure, and inhibition.

Authors:  Maris A Cinelli; Ha T Do; Galen P Miley; Richard B Silverman
Journal:  Med Res Rev       Date:  2019-06-13       Impact factor: 12.944

8.  Cationic amino acid transporter 2 regulates inflammatory homeostasis in the lung.

Authors:  Marc E Rothenberg; Matthew P Doepker; Ian P Lewkowich; Monica G Chiaramonte; Keith F Stringer; Fred D Finkelman; Carol L MacLeod; Lesley G Ellies; Nives Zimmermann
Journal:  Proc Natl Acad Sci U S A       Date:  2006-09-26       Impact factor: 11.205

9.  The cationic amino acid transporter 2 is induced in inflammatory lung models and regulates lung fibrosis.

Authors:  Kathryn A Niese; Monica G Chiaramonte; Lesley G Ellies; Marc E Rothenberg; Nives Zimmermann
Journal:  Respir Res       Date:  2010-06-24

Review 10.  Heterogeneity of microglial activation in the innate immune response in the brain.

Authors:  Carol A Colton
Journal:  J Neuroimmune Pharmacol       Date:  2009-08-05       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.